Aziyo Biologics Inc. (AZYO) News
Filter AZYO News Items
AZYO News Results
|Loading, please wait...|
AZYO News Highlights
- AZYO's 30 day story count now stands at 5.
- Over the past 9 days, the trend for AZYO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about AZYO are MD, ARC and DOCS.
Latest AZYO News From Around the Web
Below are the latest news stories about Aziyo Biologics Inc that investors may wish to consider to help them evaluate AZYO as an investment opportunity.
SILVER SPRING, Md., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 42nd Annual Cowen Health Care Conference. Date: Wednesday, March 9, 2022Format: Fireside chat and 1x1 meetings The fireside chat will be hosted at 12:50 p.m. ET. A live and arc
Aziyo Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022
SILVER SPRING, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its fourth quarter and full year 2021 earnings results after market close on Thursday, March 3, 2022. Management will host a conference call to review the Company’s financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.
Aziyo Biologics, Inc. (AZYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how Aziyo Biologics, Inc. (AZYO) and Doximity (DOCS) have performed compared to their sector so far this year.
DALLAS, TX / ACCESSWIRE / January 18, 2022 / Aziyo Biologics, Inc. (NASDAQ:AZYO): The full report can be accessed by clicking on the following link: http://stonegateinc.
Wall Street Analysts See a 123% Upside in Aziyo Biologics, Inc. (AZYO): Can the Stock Really Move This High?
The consensus price target hints at a 123.3% upside potential for Aziyo Biologics, Inc. (AZYO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference. A Pre-recorded presentation will be available on Monday, January 10th at 7:00 am Eastern Time. Interested parties may
Aziyo Biologics, Inc. (NASDAQ:AZYO) Analysts at Truist Securiti boosted their FY2021 EPS estimates for Aziyo Biologics in a report released on Tuesday, December 21st. Truist Securiti analyst D. Rescott now expects that the company will post earnings of ($1.83) per share for the year, up from their previous estimate of ($1.87). Truist Securiti also 
Aziyo Biologics (NASDAQ:AZYO) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, Aziyo Biologics Inc.is a regenerative medicine company. It focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, 
Denali Therapeutics (NASDAQ:DNLI) and Aziyo Biologics (NASDAQ:AZYO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a summary of recent ratings and recommmendations for Denali Therapeutics and Aziyo